Proanthocyanidin from Blueberry Leaf Extract
Suppresses Expression of Subgenomic Hepatitis C Virus RNA
Masahiko Takeshita,‡ Yo-ichi Ishida,§ Ena Akamatsu,§ Yusuke Ohmori,¶ Masayuki Sudoh,¶ Hirofumi Uto,‖ Hirohito Tsubouchi,‖ and Hiroaki Kataoka**1
From the ‡Research Division, Minami Nippon Dairy Co-op Co., Ltd., Miyazaki 885-0073,
the §Miyazaki Prefectural Industrial Support Foundation, Miyazaki 880-0303,
the ¶Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kanagawa 247-8530,
of Digestive Disease and Life-style Related Disease, Health Research
Human and Environmental Sciences, Kagoshima University, Graduate School
of Medicine and Dental Sciences, Kagoshima 890-8520, and
of Oncopathology and Regenerative Biology, Department of Pathology,
Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
To whom correspondence should be addressed: Section of Oncopathology
and Regenerative Biology, Dept. of Pathology, Faculty of Medicine,
University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692,
Japan., Tel.: Phone: 81-985-85-2809; Fax: 81-985-85-6003; E-mail: firstname.lastname@example.org
Received April 6, 2009; Revised June 12, 2009
C virus (HCV) infection is a major cause of chronic liver disease such
as chronic hepatitis, cirrhosis, and hepatocellular carcinoma. While
searching for new natural anti-HCV agents in agricultural products, we
found a potent inhibitor of HCV RNA expression in extracts of blueberry
leaves when examined in an HCV subgenomic replicon cell culture system.
This activity was observed in a methanol extract fraction of blueberry
leaves and was purified by repeated fractionations in reversed-phase
high-performance liquid chromatography. The final purified fraction
showed a 63-fold increase in specific activity compared with the initial
methanol extracts and was composed only of carbon, hydrogen, and
oxygen. Liquid chromatography/mass-ion trap-time of flight analysis and
butanol-HCl hydrolysis analysis of the purified fraction revealed that
the blueberry leaf-derived inhibitor was proanthocyanidin. Furthermore,
structural analysis using acid thiolysis indicated that the mean degree
of polymerization of the purified proanthocyanidin was 7.7, consisting
predominantly of epicatechin. Proanthocyanidin with a polymerization
degree of 8 to 9 showed the greatest potency at inhibiting the
expression of subgenomic HCV RNA. Purified proanthocyanidin showed
dose-dependent inhibition of expression of the neomycin-resistant gene
and the NS-3 protein gene in the HCV subgenome in replicon cells. While
characterizing the mechanism by which proanthocyanidin inhibited HCV
subgenome expression, we found that heterogeneous nuclear
ribonucleoprotein A2/B1 showed affinity to blueberry leaf-derived
proanthocyanidin and was indispensable for HCV subgenome expression in
replicon cells. These data suggest that proanthocyanidin isolated from
blueberry leaves may have potential usefulness as an anti-HCV compound
by inhibiting viral replication.
Hepatitis C virus (HCV)2 is often associated with the development of chronic liver diseases.
Infection by HCV causes chronic hepatitis at high rates and finally
results in liver cirrhosis and subsequent occurrence of hepatocellular
The number of people worldwide who are infected by HCV is estimated to
be over 200 million with 2 million infections in Japan (4).
The South Kyushu area of Japan, including Miyazaki prefecture, has a
high prevalence of this virus, and it is now recognized as a social
problem. There is no vaccine effective for HCV at present. The
elimination of HCV may be achieved by a combination of pegylated
α-interferon and ribavirin, a broad spectrum antiviral drug (4–6).
However, virological response to this combination therapy has been
reported to be 80% for genotypes 2 and 3, but less than 50% for genotype
1 (7, 8).
Moreover, α-interferon is associated with severe side-effects,
including leucopenia, thrombocytopenia, depression, fatigue, and
flu-like symptoms, and ribavirin is associated with side-effects such as
hemolytic anemia (9). Therefore, establishment of a new modality of treatment without serious adverse effects is still required.
the prolonged period (20–30 years) required for development of liver
cirrhosis and hepatocellular carcinoma in individuals infected with HCV,
we speculated that progression of the disease might be influenced by
daily diet. Our research project focuses on the daily use of
agricultural products that could cure or reduce the risk of disease
progression by HCV. Thus, we screened local agricultural products (1700
samples from 283 species) for their suppressive activity against HCV
subgenome expression using an HCV replicon cell system. We found a
significant suppressive activity in extracts of blueberry leaves.
Blueberries are classified in the genus Vaccinium, and the
species are native only to North America. Blueberry leaves have high
quinic acid and chlorogenic acid contents and also significant flavonol
glycosides such as rutin. Thus, they are high in antioxidant activity.
In our subsequent screening studies using various kinds of blueberry
species, the most potent activity was observed in the leaf of rabbit-eye
blueberry (Vaccinium virgatum Aiton), which is cultivated in southern areas of Japan.
this study, extracts of rabbit-eye blueberry leaves were used in an
effort to purify and identify the compound responsible for inhibition of
the expression of subgenomic HCV RNA. We identified oligomeric
proanthocyanidin with mean degree of polymerization (mDP) around eight
as an inhibitor of HCV subgenome expression. We also analyzed cellular
proteins that have affinity to the oligomeric proanthocyanidin in HCV
replicon cells and identified heterogeneous nuclear ribonucleoprotein
(hnRNP) A2/B1 as one of candidate proteins involved in the
proanthocyanidin-mediated inhibition of HCV subgenome expression.
Extraction of Blueberry Leaves
A lyophilized powder made from leaves of rabbit-eye blueberry (V. virgatum Aiton) was provided by Unkai Shuzo Co., Ltd. (Miyazaki, Japan). One
gram of the lyophilized powder was extracted with 100 ml of methanol at
room temperature with shaking for 15 min, and the supernatant was passed
through filter paper (filter paper No.2, Toyo, Tokyo, Japan). The
methanol extract was then extracted with 100 ml of chloroform, followed
by centrifugation (1750 × g for 10 min), and the resultant
precipitate and supernatant were collected. The precipitate was
dissolved in methanol, concentrated in vacuo, and lyophilized
(CMW-ppt). The supernatant was mixed with 150 ml of distilled water and
methanol to perform a liquid-liquid extraction, and the water layer was
collected and mixed with 150 ml of chloroform to repeat the chloroform
extraction. The water layer was concentrated and lyophilized (CMW-W).
The chloroform layer was also concentrated and lyophilized (CMW-C). Most
HCV subgenome-expression inhibitory activity was recovered in the CMW-W
Preparative Fractionation by HPLC
separate the components in the CMW-W fraction processing inhibitory
activity against HCV RNA expression, we performed HPLC (Prominence
System, Shimadzu, Kyoto, Japan). Preliminary fractionation of CMW-W to
confirm the elution pattern of HCV expression suppressive components was
carried out on a reversed-phase column (Atlantis dC18, 4.6 mm × 150 mm,
3 μm, Waters, Milford, MA) at 40 °C with UV detection at 254 nm. A
gradient consisting of eluant A (0.05% trifluoroacetic acid) and eluant B
(acetonitrile) was applied at a flow rate of 0.7 ml/min as follows:
15–25% B linear from 0 to 12.5 min, 25–100% B linear from 12.5 to 17.5
min followed by washing 100% B from 17.5 to 25 min. For purification,
the first HPLC fractionation was performed on a reversed-phase column
(Atlantis T3, 4.6 mm × 150 mm, 3 μm, Waters). A gradient consisting of
eluant A and eluant B (acetonitrile) was applied at a flow rate of 0.7
ml/min as follows: 30% B from 0 to 7.5 min, 30–100% B linear gradient
from 7.5 to 12.5 min, followed by washing with 100% B from 12.5 to 20
min. The CMW-W fraction dissolved in 30 ml of methanol was injected, and
the eluted fractions (2.1 to 18.0 min, total 26 fractions) were
collected. The gradient program for the second fractionation was 20% B
from 0 to 7.5 min, 20–100% B linear from 7.5 to 12.5 min, followed by
washing with 100% B from 12.5 to 20 min. Fractionation of the eluate was
the same as the first HPLC program. In the third HPLC fractionation,
the eluant B was replaced by methanol and eluted with 40–65% B linear
gradient from 0 to 12.5 min and 65–100% B linear gradient from 12.5 to
17.5 min. Fractions eluted from 2.2 to 17.5 min (total 26 fractions)
were collected. In all experiments, suppressive activity of each
fraction against HCV RNA expression was measured using replicon cells.
HCV Replicon Cells and Replicon Assay
The Huh-7/3-1 cell line carrying an HCV-replicon was used (10).
The line was established from Huh-7 cells by stable transfection with
subgenomic selectable RNA in which the encoding HCV structural proteins
were replaced by the firefly luciferase gene, the internal ribosome
entry site (IRES) of the Encephalomyocarditis virus and the
neomycin phosphotransferase gene. With this HCV subgenome, the
efficiency of subgenomic HCV expression could be estimated by measuring
luciferase activity in the replicon cells. The HCV replicon cells were
routinely grown in Dulbecco's modified Eagle's medium supplemented with
Glutamax (Invitrogen), 10% fetal bovine serum, 1%
penicillin/streptomycin (Invitrogen), and 500 μg/ml G418 (Invitrogen).
Cells were maintained at 37 °C in a humidified atmosphere containing 5%
CO2. For the HCV subgenome expression assay, the replicon
cells in Dulbecco's modified Eagle's medium supplemented with Glutamax
and 5% fetal bovine serum were seeded in 96-well plates (5000
cells/well) and incubated for 24 h. Then the cells were cultured with
various concentrations of samples for 72 h. Quantification of the
luciferase activity was performed using the Steady-Glo Luciferase Assay
System (Promega, Madison, WI) according to the manufacturer's
instructions, and the luminescence was measured by DTX 800 Multimode
Detector (Beckman Coulter, Fullerton, CA). The inhibitory activity was
expressed as the concentration required for 50% inhibition (IC50). Specific activity was calculated as a reciprocal number of IC50 (1/IC50). Total activity was calculated by multiplying yielded weight by specific activity.
cytotoxicity of the samples was measured by Cell Counting Kit-8
(Dojindo Molecular Technologies, Kumamoto, Japan) according to the
manufacturer's instructions. Briefly, 10 μl/well of Cell Counting Kit-8
reagent was added to the cells cultured in a 96-well plate, incubated at
37 °C for 60 min. The absorbance of each well was measured at 450 nm
with a reference wavelength at 650 nm using an Emax Precision microplate
reader (Molecular Devices Inc., Sunnyvale, CA). Cell viability was
calculated as relative index of control cells, and effects of samples on
cell viability were expressed as the concentration required for 50%
Analysis of Electron Probe Micro-analysis and Liquid
Chromatography/Mass Spectrometry-ion Trap-time of Flight (LC/MS-IT-TOF)
electron probe micro-analysis (EPMA-1600, Shimadzu), the excitation
voltage and the beam current were kept at 15 kV and at 100 nA,
respectively. The diameter of the electron beam was 50 μm, and the
sample was processed for carbon shadowing in advance.
of the anti-HCV compound purified from blueberry leaves was done by
HPLC-MSn fragmentation analyses. An HPLC System (Prominence System,
Shimadzu) on a reversed-phase column (Atlantis T3, 2.1-mm inner diameter
× 100 mm, 3 μm, Waters) was equipped with a photodiode array (PDA)
detector scanning from 200 to 800 nm and mass spectrometry-ion trap-time
of flight (MS-IT-TOF, Shimadzu) detector. The mobile phase consisted of
a gradient system 30 min of eluant A (0.05% trifluoroacetic acid) and
eluant B (acetonitrile) at a flow rate of 0.25 ml/min. The elution
program was 10–25% B linear from 0 to 7.5 min, 25–100% B linear from 7.5
to 12.5 min, followed by washing 100% B from 12.5 to 20 min. The column
was maintained at 40 °C. Electrospray ionization conditions were
recorded from m/z = 200 to 1500 in a negative
ionization mode. Other MS conditions were as follows: interface voltage,
−3.5 or −3.0 kV; nebulizer N2 gas, 1.5 or 2.0 liters/min; drying N2 pressure, 200 or 70 kPa, respectively. Heat block temperature and
curved desolvation line temperature were both 200 °C. Analytical
conditions were recorded from m/z 250 to 1500 in a
negative ionization mode. Atmospheric pressure chemical ionization
(APCI) probe temperature was set from 250 to 450 °C.
Analysis of Proanthocyanidin
Proanthocyanidins were characterized by a modified method of Porter et al. (11, 12),
in which they were degraded to anthocyanidins by heating under acidic
conditions. Briefly, 200 μl of purified compound from blueberry leaves
(0.1–2.5 mg/ml) was mixed with 750 μl of n-butanol/HCl (95:5) and 50 μl of 1% of NH4Fe(SO4)2·12H2O dissolved in 2 m HCl. The mixture was vortexed and heated in an oven at 105 °C for 40
min, and cooled in flowing water. Optical densities of the treated
solution were recorded at 540 nm by spectrophotometer (UV-1700,
Shimadzu). Procyanidin B2 (Sigma-Aldrich) was used as a standard. The
hydrolysates generated by the modified Porter method were also analyzed
using LC/MS-IT-TOF as described above. The elution program was 10–40% B
linear from 0 to 15 min followed by washing 100% B from 15 to 22.5 min.
Electrospray ionization conditions were recorded from m/z 200 to 1500 in a positive ionization mode. Interface voltage and nebulizer N2 were 4.5 kV and 1.5 L/min, respectively. MS/MS conditions were set to auto system and recorded from m/z 50 to 1000. The parent MS was searched from m/z 200 to 1500, and ion accumulation was 30 ms. The data were analyzed by
LCMS solution v3.41 software and Formula Predictor Software (Shimadzu).
Thiolysis was performed by a previously described method (13, 14)
with some modifications. Briefly, 50 μl of purified samples (2 mg/ml in
methanol) was mixed with 50 μl of methanol acidified with HCl (3.3%)
and 100 μl of benzyl mercaptan (5% in methanol). The reaction was
carried out at 50 °C for 30 min and then kept at ambient temperature for
3 h. Pure catechin or epicatechin solution (1.25 mg/ml in methanol)
(Funakoshi, Tokyo, Japan) was also thiolyzed to obtain the epimerization
rate to calculate the ratio of catechin and epicatechin in the terminal
units. The reaction mixture was diluted 5-fold with methanol and
analyzed by reverse-phase HPLC. An Atlantis T3 column (4.6 mm × 150 mm, 3
μm, Waters) was used at 40 °C as described above. UV detection was
performed at 280 nm. The gradient program was 15–25% B linear from 0 to
10 min, 25–100% B linear from 10 to 30 min, followed by washing 100% B
from 30 to 37.5 min and re-equilibration of the column 37.5 to 45 min
under initial gradient conditions. To ascertain the elution pattern of
thiolysis media and to estimate unknown peaks, LC/MS-IT-TOF was also
employed in a negative ion mode. Flavan-3-ols and their benzylthio
adducts obtained by thiolysis media of procyanidin B2 were used as a
standard. The mDP was calculated by the formula, mDP = [sum of
(benzylthio adducts × n) + sum of (free flavan-3-ol × n)]/[total free flavan-3-ol], in which “n” is DP of detected flavan-3-ol by thiolysis.
Preparation of Proanthocyanidin from Blueberry Leaves
prepare proanthocyanidin from blueberry leaves, freeze-dried powder
(100 g) was extracted with 1.2 liters of acetone for 10 min, and the
supernatant was decanted. This procedure was repeated five times to
remove the green pigment from the leaves, followed by washing in 1.2
liters of hexane for 30 min. The remaining residues were washed with
ethyl acetate. The washed powder of leaves was extracted with 1.2 liters
of methanol for 30 min, and the supernatant was filtered. This
procedure was repeated four times, and the resulting crude methanol
extracts were concentrated by rotary evaporator at 50 °C and
lyophilized, finally resulting in ~30 g of solid powder. The crude
methanol extract (15 g) was then dissolved in 1.0 liter of 60% methanol
and placed on a Sephadex LH-20 column (50 mm × 920 mm, Amersham
Biosciences). Fractionation was performed using the following series of
solvents: fraction I, 9.0 liters of 60% methanol (retrieved weight: 10.2
g); fraction II, 9.0 liters of 100% methanol (retrieved weight: 3.3 g);
fraction III, 9.0 liters of 70% (v/v) acetone (retrieved weight: 1.3
g). The LC/MS-IT-TOF analyses of each fraction indicated that fraction I
was primarily composed of quinic acid, chlorogenic acid, and flavonol
glycosides such as rutin. Fraction II consisted of proanthocyanidin
oligomers from tetramer to decamer as analyzed by thiolysis. Fraction
III consisted of proanthocyanidin polymers that were decamers or
greater. In each fraction, the eluate was divided into 28
Northern Blot Analysis
RNAs from cultured replicon cells were prepared using RNeasy mini kits
(Qiagen). RNAs were denatured at 65 °C for 15 min, cooled on ice, and
then separated by 1% agarose-formaldehyde gel electrophoresis (2
μg/lane) and transferred to a positively charged nylon membrane
(Hybond-N+, Amersham Biosciences). The membrane was
hybridized with a biotinized probe of the neomycin phosphotransferase
gene. For detection of the bound probe, membranes were incubated with
streptavidin-Alexa Fluor 680 conjugate (Invitrogen), and the bound
fluorescence was detected by Odyssey Infrared Imaging System (LI-COR
Biosciences). For internal control, β-actin mRNA-specific biotinized
antisense RNA probe was used.
Western Blot Analysis
replicon cells were harvested, and total cellular proteins were
extracted with CelLytic-M (Sigma-Aldrich) containing 1% protease
inhibitor mixture (Sigma-Aldrich). The samples were separated by
SDS-PAGE using 10% gel under reducing conditions. The proteins were
transferred electrophoretically to an Immobilon-P membrane (Millipore,
The membrane was
treated with a blocking buffer for near infrared fluorescent Western
blotting (Rockland, Gilbertsville, PA). Primary antibodies used were
anti-human hnRNP A2/B1, hnRNP K, hnRNP L, and hnRNP Q and anti-human
β-actin antibodies (EF-67, D-6, A-11, 18E4, and I-19, respectively,
Santa Cruz Biotechnology, Santa Cruz, CA), anti-human eukaryotic
translation initiation factor 3 (eIF3) F, eIF3G eIF3H polyclonal
antibodies (Novus Biologicals, Littleton, CO), and anti-HCV NS-3
polyclonal antibody (10). The labeled proteins were visualized with Alexa Fluor 680 anti-rabbit or anti-mouse IgG (Invitrogen) or IRDyeTM 800CW anti-goat IgG (LI-COR Biosciences) and detected by using as Odyssey Infrared Imaging System.
Affinity Purification of Proanthocyanidin-binding Proteins
blueberry leaf-derived proanthocyanidin or catechin was coupled with
epoxy-activated Sepharose 6B (Amersham Biosciences) according to the
manufacturer's instructions. Approximately 5 × 108 HCV replicon cells were extracted with lysis buffer (50 mm sodium phosphate (pH 7.5), 1% CHAPS, 5 mm EDTA, 150 mm NaCl, and protease inhibitor mixture (CompleteTM,
Roche Diagnostics, Mannheim, Germany)). The total protein extract (90
mg) was added to the coupled Sepharose beads (3 ml) and incubated at 4
°C overnight with gentle rotation. The beads were centrifuged (500 × g)
for 1 min, and the pellet was washed six times with the lysis buffer.
The absorbed proteins were eluted by incubation in 2% SDS with 50 mm dithiothreitol at 100 °C for 10 min. The eluate was concentrated with
an Amicon Ultra-4 Ultracel-5k (Millipore), and the solvent was replaced
by the lysis buffer. Protein concentration was determined by the o-phthalaldehyde method using bovine serum albumin as the standard.
Fluorescent Two-dimensional DIGE
two-dimensional-DIGE was performed using fluorescent dyes, IC3-OSu and
IC5-OSu (Dojindo Molecular Technologies), with a modification of the
methods reported elsewhere (15, 16).
Briefly, 10 μg of proteins per gel were precipitated using a
two-dimensional clean-up kit (Bio-Rad) and then dissolved in 20 μl of
sample buffer (10 mm sodium phosphate (pH 8.0), 7 m urea, 2 m thiourea, 3% CHAPS, and 1% Triton X-100). After addition of 400 pmol of
IC3-OSu or IC5-OSu, proteins were incubated at 40 °C for 30 min. The
labeling reaction was quenched by incubation with 400 μm lysine for 15 min, followed by addition of an equal volume of the sample buffer with 150 mm dithiothreitol, 0.4% Bio-Lyte 3–10 (Bio-Rad Laboratories), and 0.004%
bromphenol blue. Two-dimensional gel electrophoresis was performed
according to the manufacturer's instructions (Bio-Rad). The mixed
samples were applied to ReadyStrip IPG strips (pH 3–10 NL, 7 cm,
Bio-Rad) for separation in the first dimension. The second-dimensional
separation was performed by SDS-PAGE using an 8% gel. Fluorescence
imaging was performed on a ProxpressTM proteomic imaging
system (PerkinElmer Life Sciences). IC3-OSu-labeled proteins were
detected with 540/25 nm excitation and 590/35 nm emission filters.
IC5-OSu-labeled proteins were detected with 625/35 nm excitation and
680/30 nm emission filters. In this study, while proteins from
proanthocyanidin- or catechin-coupled Sepharose were labeled with
IC5-OSu, a mixture of equal quantities of both samples was labeled with
IC3-OSu and used as a reference for quantitation of IC5-OSu-labeled
proteins as described (16).
The fluorescent images were aligned using SameSpot TT900 S2S (Nonlinear
Dynamics, Newcastle, UK) and then analyzed with Progenesis Discovery
software (Nonlinear Dynamics). Each group (eluate from proanthocyanidin-
or catechin-coupled Sepharose) was run on triplicate gels three times.
Spot intensity in the IC5-OSu image was normalized to the intensity of
the corresponding IC3-OSu image spot in the same gel. The average spot
intensities ± standard deviation (S.D.) from nine gels were calculated.
Statistical differences were determined by Student's t test, and p values <0.05 were considered significant. The proteins having high
affinity to proanthocyanidin but not to catechin were detected using a
1.5-fold change (p < 0.05) as the cut off.
Protein identification by peptide mass fingerprinting was performed as described previously (17).
Briefly, 100 μg of proteins was separated by two-dimensional-DIGE gels
and stained with Coomassie Brilliant Blue R-250. Protein spots of
interest were excised from the gel and digested overnight with trypsin.
Each peptide extract was deposited onto a thin layer of
α-cyano-4-hydroxycinnamic acid (Bruker Daltonics, Bremen, Germany) and
allowed to adsorb for 5 min, after which the layers were washed twice
with 0.1% trifluoroacetic acid. Spectra were obtained using
matrix-assisted laser desorption/ionization-TOF-TOF-MS, Autoflex II
TOF/TOF (Bruker Daltonics) in positive-ion and reflectron mode. The data
set was entered in an in-house Mascot search engine (Matrix Science,
London, UK), to find the closest match with known proteins registered in
the data base from the Swiss-Prot.
Knockdown of Proanthocyanidin-binding Proteins Using siRNAs
SMARTpools of duplex siRNAs targeting hnRNP L, hnRNP K, hnRNP A2/B1,
hnRNP A/B, hnRNP Q, eIF3F, eIF3G, eIF3H, and non-targeting control siRNA
were purchased from Dharmacon (Thermo Fisher Scientific, Tokyo, Japan).
Individual sequence of hnRNP A2/B1 siRNAs was confirmed by two single
siRNAs (Target #09: 5′-CGGUGGAAAUUUCGGACCA-3′, Target #11:
5′-GGAGAGUAGUUGAGCCAAA-3′). The replicon cells were transfected with
each siRNA using Lipofectamine RNAiMAX reagent (Invitrogen) according to
the manufacturer's protocol. After 72 h incubation, the cells were
Purification of an Inhibitor of HCV Subgenome Expression from Blueberry Leaves
screened 283 species of local agricultural products for their
suppressive activity against the expression of subgenomic HCV RNA using
an HCV replicon cell system, and found significant suppressive activity
in the leaves of the blueberry (Vaccinium virgatum Aiton), peels of roots of Taro (Colocasia esculenta L.), and hulls of seeds of Japanese plum (Prunus mume Sieb. et Zucc). Among them, extracts of blueberry leaves contained the highest
total activities. Therefore, we purified a compound from blueberry
leaves that inhibited expression of subgenomic HCV RNA in replicon
cells. An overall purification scheme is shown in , and a summary of the purification steps is shown in . From 1000 mg of lyophilized powder from the leaves, 440 mg of methanol extracts was obtained. The IC50 value of the methanol extracts was 5.47 μg/ml. The inhibitory activity
was recovered in the CMW-W fraction (284.2 mg), in which the IC50 value was 1.74 μg/ml. The specific activity of CMW-W was 3-fold greater
than that of the initial methanol extracts and the yield of the
activity exceeded 200%, suggesting that an interfering substance had
Fractionation of blueberry leaf extract for the inhibitor of HCV subgenome expression. The inhibitory activity was indicated under each fraction as the IC50 value (micrograms/ml).
Purification of HCV subgenome expression inhibitory activity in blueberry leaf
CMW-W fraction was subjected to a subsequent HPLC purification step in
which a preliminary HPLC elution pattern (a 15–100% gradient of
acetonitrile) was used. The data indicated that a strong inhibitory
activity eluted around 90% of acetonitrile (17 min) with some minor
inhibitory activities broadly eluted earlier. Those results suggested
the possible existence of multiple HCV subgenome expression inhibitors
in the CMW-W fraction (A).
To purify the most active component, we initially separated the CMW-W
isocratic at 30% acetonitrile and collected the active fraction eluted
at 3.3–5.2 min (B). After repeated collection, we obtained 140.2 mg of active fraction (LC1) from 440 mg of methanol extracts. The IC50 value of this fraction for HCV RNA expression was 0.89 μg/ml, yielding a
specific activity 6-fold higher than that of the initial methanol
extracts (). In the second round HPLC (C),
we fractioned LC1 as follows: 20% acetonitrile from 0 to 7.5 min,
followed by 20–100% linear gradient of acetonitrile from 7.5 to 12.5
min. A highly active fraction was eluted from 11.9 to 13.2 min and
collected (LC2), yielding 24.6 mg with an IC50 value 0.54 μg/ml (). In the third HPLC step (D),
we applied LC2 and eluted with 40–65% methanol instead of acetonitrile.
The active fraction was eluted from 3.2 to 6.2 min and collected (LC3),
finally yielding 2.9 mg of solid material with a dark flesh color. The
IC50 value for HCV RNA expression of LC3 was 0.087 μg/ml,
with a 63-fold increase in specific activity relative to the initial
methanol extracts (). We also checked the cytotoxic effect on replicon cells. The CC50 value of the cytotoxicity of LC3 was 18.5 μg/ml, and the selective index, which was calculated by dividing CC50 by IC50, was 212.6, showing a 16.5-fold higher selective index value compared with initial methanol extracts ().
HPLC chromatogram and HCV subgenome expression-inhibitor activity. Replicon assays were performed using three different concentrations
(1%, 5%, and 10%) of each eluted fraction and are indicated as
Dose-dependent effects of blueberry-derived samples on subgenomic HCV RNA-expression inhibition and viability of replicon cells. A, dose-dependent effects of methanol extracts of blueberry leaves. Concentrations of the sample from 0.112–2200 μg/ml
The Inhibitor of HCV Subgenome Expression Is Proanthocyanidin
analyze the constituent elements in the purified fraction LC3, EPMA was
performed. This analysis indicated that the fraction is composed of
carbon and oxygen, but not nitrogen (data not shown). In addition, trace
amounts of calcium, sodium, potassium, and aluminum, which appeared to
be contaminating elements, were also identified. Next, LC3 was analyzed
by LC/MS-IT-TOF. Preliminary trials showed that analysis required the
use of an APCI probe at 450 °C, and no signal was obtained at 250 °C.
The mass spectrum data showed five peaks (), and [M-H]− at m/z 401.0494 and 689.1135 were considered to be trifluoroacetic acid adducts of m/z 287.0553 and 575.1196, respectively. From these spectra, the parent mass of this compound appeared to be [M-H]− at m/z 575.1196, which was estimated to be C30H24O12 (error = 0.17 ppm), an A-type dimer of procyanidin. Given the fact that
strict conditions (APCI probe temperature at 450 °C) were required to
ionize the compound, it appeared that the isolate consisted of one or
more polymers of procyanidin.
APCI MS spectra of the LC3 fraction. The total-ion chromatogram of the LC3 fraction was further analyzed by APCI MS. Peaks of m/z 401.0494 and m/z 689.1135 were considered to be trifluoroacetic acid adducts of m/z 287.0553 and m/z 575.1196, respectively.
We next analyzed the purified LC3 fraction by butanol-HCl hydrolysis (Porter method) (11
The reacted solution turned a red color, which is in accordance with
the color of anthocyanidin generated by heating of
procyanidin/proanthocyanidin under acidic condition. Using procyanidin
B2 as a standard, the procyanidin content in the LC3 fraction was
86.33%. The hydrolysis solution was analyzed by LC/MS-IT-TOF. The main
peak (retention time = 7.3 min) of the PDA chromatogram at 540 nm was
observed at the same position as that of the cyanidin standard (A
). Indeed, MS/MS spectra of this peak were identical to those of the cyanidin standard (B
These results revealed that the HCV RNA replication inhibitory compound
present in the LC3 fraction from blueberry leaves was procyanidin.
Because the hydrolysate of this compound also contained a trace amount
of delphinidin (A
), this compound was considered to be proanthocyanidin rather than procyanidin.
PDA chromatogram and MS/MS spectra of the hydrolysate of the purified fraction by the Porter method. A, PDA chromatogram at 540 nm of hydrolysate of purified fraction from blueberry leaves.
Structural Analysis of the Inhibitory Proanthocyanidin by Thiolysis
analyze the terminal and extension units and also define mDP of
proanthocyanidin in the purified LC3 fraction of blueberry leaves, we
combined thiolysis (13)
with reversed-phase HPLC. When thiolysis products of purified
proanthocyanidin in the LC3 fraction were analyzed in reversed-phase
HPLC, several peaks (A–H) were identified (). The peaks A, C, and H were considered to be catechin, epicatechin, and benzylmercaptan,
respectively, according to the retention time of each standard
preparation. Other peaks were confirmed by analyzing mass spectra. The
parent mass of peak E was [M-H]− at m/z 411.0892, with an estimated formula of C22H20O6S (error = −3.8 ppm), and its MS/MS spectrum was [M-H]− at m/z 287.0510. The difference between the parental mass and MS/MS was
124.0382, which was in accordance with a benzylthio adduct. Thus, peak E
appeared to be catechin or epicatechin benzylthioether. Because the
retention time of epicatechin benzylthioether was the same as that of
peak E, we considered peak E to be epicatechin benzylthioether. The
parental mass of peak G was [M-H]− at m/z 697.1385 (predicted formula: C37H30O12S), and its MS/MS was [M-H]− at m/z 573.0987. Again, the difference was 124.0398 and likely represented the
benzylthio adduct. Thus, peak G was estimated to be a benzylthioether
of A-type dimer consisting of catechin and/or epicatechin. Peak B was
detected as parent MS [M-H]− at m/z 863.1822 with a predicted formula C45H36O18 (error = −0.86 ppm). Because the formula of B-type procyanidin trimer is C45H38O18 and that of A-type is C45H34O18,
this peak was likely a trimer in which A-type and B-type interflavan
bonds coexisted. Peak D was suggested to be an A-B type trimer similar
to peak B but with a benzylthio adduct. The parental mass of peak F was
[M-H]− at m/z 605.1449, and its MS/MS was [M-H]− at m/z 481.1109, so that a benzylthio adduct was also present in peak F.
However, we could not obtain the predicted formula of the parental mass
of peak F. The structural analysis of the HCV inhibitor proanthocyanidin
from blueberry leaves (fraction LC3) is summarized in .
The mDP of proanthocyanidin in this fraction was estimated to be 7.7.
Because the predicted formula of peak F was undefined, peak F is
indicated as “unknown” in .
HPLC chromatogram at 280 nm of thiolysis products of LC3 fraction from blueberry leaves. Peaks A, C, and H were identified as catechin, epicatechin, and benzylmercaptan, respectively. Peak E was identified as epicatechin benzylthioether.
Thiolysis results of purified fraction (LC3) from blueberry leaves
Role of Polymerized Structure of Proanthocyanidin in the Inhibition of HCV Subgenome Expression
the purified HCV expression-inhibitory proanthocyanidin of blueberry
leaf was oligomer with mDP 7.7, we asked whether the polymerization was
required for inhibitory activity. First, the inhibitory activities of
monomers such as catechin, epicatechin, and epigallocatechin-gallate,
all of which were constituents of proanthocyanidin, and also of the
dimer (procyanidin B2) were tested by HCV replicon assay. These monomers
and the dimer of procyanidin lacked inhibitory activity ().
Effects of constitutional units of proanthocyanidin on expression of HCV subgenome in replicon cells
then determined how the degree of polymerization of proanthocyanidin
affected the inhibition. The crude fraction of proanthocyanidins was
obtained by the extraction of three low polarity solvents
(acetone-hexane-ethyl acetate) as described under “Experimental
Procedures.” The IC50
of HCV RNA expression of this
proanthocyanidin-enriched fraction was 3.20 μg/ml, showing greater
activity than the crude methanol extract. After fractionation on a
Sephadex LH-20 column, each eluant was analyzed by LC/MS-IT-TOF and
thiolysis to determine the components and mDP of proanthocyanidin (supplemental Fig. S1
Then, the blueberry leaf-derived proanthocyanidins with different mDP
were assessed for HCV inhibitory activity. The inhibitory activity of
blueberry leaf proanthocyanidin was clearly dependent on the
polymerization level, and the peak activity was observed at a
polymerization level of ~8 to 9 (IC50
: 0.05 μg/ml) ().
Scatter plot of mDP and specific activity of subgenomic HCV RNA-expression inhibition. The mDP was estimated by thiolysis of each fraction. The specific activity was calculated from IC50 value of each fraction.
Effect of Purified Blueberry Proanthocyanidin
on the Expression of NS3 HCV Protein in Replicon Cells
our system, HCV RNA expression in replicon cells was expressed as
luciferase activity. Thus, the observed inhibitory activity may have
resulted from nonspecific inhibition of luciferase by proanthocyanidin.
Therefore, we examined the effect of the purified proanthocyanidin
(fraction LC3) on the expression levels of the neomycin-resistant gene
and the NS3 protein gene, both of which were encoded in the HCV
subgenome of replicon cells. The purified blueberry proanthocyanidin
suppressed the expression of the neomycin-resistant gene and also the
levels of NS3 protein in a concentration-dependent manner, indicating
that the proanthocyanidin purified from blueberry leaves in fact
suppressed the expression of HCV subgenome in the replicon cells ().
effects of purified blueberry leaf proanthocyanidin (LC3 fraction) on
the expression of the neomycin resistant gene and NS-3 protein in
hnRNP A2/B1, Which Has Affinity to Proanthocyanidin,
Is Indispensable for Expression of Subgenomic HCV RNA
investigate the molecular mechanism underlying the suppression of HCV
RNA expression by proanthocyanidin, we comprehensively identified
proteins having affinity to the purified proanthocyanidin from blueberry
leaves. The protein extract from replicon cells was treated with
proanthocyanidin-coupled Sepharose, and then the adsorbed proteins were
eluted. The extract was also treated with Sepharose beads coupled to
catechin, a structural unit of proanthocyanidin, but HCV
subgenome-expression inhibitory activity was not observed (). The proteins having higher affinity to proanthocyanidin than catechin were detected with fluorescent two-dimensional-DIGE ().
In the eluate from proanthocyanidin-coupled Sepharose, intensities of
32 spots were increased compared with those from catechin-coupled
Sepharose. Twenty-seven spots were cut from Coomassie-stained gels and
subjected to peptide mass fingerprinting using MS, and we successfully
identified proteins derived from 25 spots (Nos. 1 to 25 in A and ). Although other possible candidate spots were also suggested in a rectangular portion (A), they were not subjected to protein identification due to insufficient separation.
Fluorescent two-dimensional-DIGE images of proteins with affinities to blueberry leaf proanthocyanidin (A) and catechin (B). Protein extracts from replicon cells were treated with epoxy-activated Sepharose coupled to proanthocyanidin or catechin.
Proteins with higher affinity to blueberry proanthocyanidin than to catechin
From the list of identified proteins (),
most could be categorized into two groups. The first group consisted of
subunits of eukaryotic translation initiation factor 3 (eIF3). They
included eIF3A (spot Nos. 1, 5, and 9), eIF3F (No. 10), eIF3G (No. 12),
eIF3H (No. 4), and eIF3M (No. 13). Although eIF3A was identified from
multiple protein spots (Nos. 1, 5, and 9), this may be due to
post-translational modification and protein processing. The second group
of proteins consisted of hnRNPs such as hnRNP A/B (No. 19), hnRNP A2/B1
(No. 8), hnRNP K (Nos. 17 and 22), hnRNP L (Nos. 11, 15, and 21), and
hnRNP Q (Nos. 2, 6, and 7) also known as NS1-associated protein 1.
Importantly, eIF3 has been reported to bind directly to the HCV internal
ribosome entry site (IRES), leading to translation initiation of viral
Moreover, all hnRNPs identified have been reported to be associated
with HCV genomic RNA such as IRES and non-translated regions (19–25).
These results imply that proanthocyanidin may target cellular proteins
such as eIF3 and hnRNPs. To further clarify the relationship between
these proteins and HCV subgenome expression, we examined the effects of
siRNA-based knockdown of these proteins (supplemental Fig. S2). First, we selected three eIF3 subunits (eIF3F, eIF3G, and eIF3H), which are thought to be involved in IRES binding of eIF3 (26).
However, knockdown of these subunits did not affect the luciferase
activity in replicon cells. Then, we targeted all hnRNPs identified.
Among them, siRNA pool targeting hnRNP A2/B1 significantly suppressed
the luciferase activity of HCV subgenomic replicon cells (supplemental Fig. S2), and this result was confirmed using two kinds of single siRNA (). Weak suppressive activities were also suggested by siRNAs targeting other hnRNPs such as hnRNP A/B, K, and L (supplemental Fig. S2).
Effects of hnRNP A2/B1 knockdown on HCV subgenome expression in replicon cells. Results of two siRNA sequences (si-#09 and si-#11) are shown. A, effects of siRNA on the expression of hnRNP A2/B1 protein. Same blot was also probed by anti-actin antibody.
HCV infection is a major cause of chronic liver disease, which
eventually results in end-stage liver diseases such as cirrhosis and
hepatocellular carcinoma. A crude extract from rabbit-eye blueberry (V. virgatum Aiton) leaves exhibited significant inhibitory activity against HCV RNA
expression when analyzed in HCV subgenomic replicon cells. In this
study, we attempted to purify a compound that suppresses HCV subgenome
expression from the blueberry leaves. The final purified product was
identified as proanthocyanidin, and it was effective at concentrations
that are two orders of magnitude below the toxic threshold in replicon
cells. The mDP of the proanthocyanidin in purified anti-HCV expression
fraction was 7.7 with a high proportion of epicatechin as the monomeric
components. Subsequent analysis indicated that the blueberry
leaf-derived proanthocyanidin with a degree of polymerization of ~8–9
shows the highest inhibitory activity. Finally, the purified
proanthocyanidin from blueberry leaf extracts suppressed the expression
of the neomycin phosphotransferase gene and the NS-3 protein gene in HCV
subgenome replicon cells in a dose-dependent manner. These data suggest
the potential value of blueberry leaf proanthocyanidin for the
treatment of HCV infection.
is a polyphenol that shows polymerization of more than two units of
flavan-3-ol such as catechin and epicatechin (supplemental Fig. S3).
There are two interflavan bonds in proanthocyanidin, in which the
B-type has one linkage of interflavan bond (C4 → C8 or C4 → C6) and the
A-type has two linkages of bonds (C4 → C8 and O7 → C2) (27).
Proanthocyanidins were previously known as condensed tannin and are
present in various plants and foods. They contribute to organoleptic
properties such as stability, astringency, and bitterness (28, 29).
There are a number of foods and nutritional supplements that contain
proanthocyanidins with health-promoting benefits, and their value has
been described in the literature and patent documents. For example,
proanthocyanidin contained in blueberries increases the lifespan of the
nematode (Caenorhabditis elegans) (30). Sangre de Grado extracted from Croton lechleri resin is a traditional natural medicine in the upper Amazon and
contains hydrolyzing flavonoids, proanthocyanidins, and other
polyphenols (31, 32),
which have been shown to possess anti-viral activities against
influenza, parainfluenza, herpes simplex viruses, and respiratory
syncytial virus (33–38).
However, to the best of our knowledge, this report is the first study
to demonstrate that proanthocyanidin inhibits the expression of
subgenomic HCV RNA.
Regarding the mechanism underlying the anti-viral activities, proanthocyanidins from Croton lechleri resin and prodelphinidin B-2 3′-O-gallate
from green tea leaf inhibit herpes simplex viruses infection by
preventing the attachment and penetration of the virus into the target
cells (37, 39). Recently, the grapefruit flavonoid naringenin was reported to inhibit apolipoprotein B-dependent HCV secretion (40).
However, in this study, we evaluated the inhibitory effect on HCV
subgenome expression by measuring luciferase activity in replicon cells
without using actual viral particles. Therefore, the mode of anti-HCV
action of proanthocyanidin is different from that in herpes simplex
viruses infection mentioned above and is also different from the
inhibitory mechanism of naringenin. Instead, our study suggests that
blueberry leaf-derived proanthocyanidin may interact with hnRNP A2/B1, a
factor required for HCV subgenome expression in our replicon assay. In
accordance with this observation, recent study has shown that hnRNP A1, a
protein highly homologous to hnRNP A2/B1, facilitates HCV replication,
and the double knockdown of hnRNP A1 and hnRNP A2 significantly
suppresses replication (23).
Alternatively, proanthocyanidin may bind to the translational
initiation complex associated with HCV IRES and thereby suppresses the
HCV subgenome expression, because a number of translational regulatory
proteins are included in our list of proanthocyanidin-binding proteins.
To date, for the inhibitors of IRES-directed translation in HCV-infected
cells, vitamin B12, a synthetic peptide derived from human La protein,
and RNA molecules targeting IRES have been reported (42–44).
However, little is known regarding the effect of natural
product-derived polyphenolic compounds on HCV IRES-directed translation,
and this possibility should be clarified in a future study. It should
be noted that all proanthocyanidin-binding proteins identified in this
study are intracytoplasmic and/or intranuclear proteins. However, it is
not known whether proanthocyanidin can be efficiently translocated into
the intracellular space despite its highly polymerized structure.
Nonetheless, absorption of proanthocyanidin from the digestive tract has
been reported (12, 45),
suggesting the possibility of proanthocyanidin internalization into
cells, and internalization of high molecular weight molecule via
clathrin-mediated endocytosis, caveolae-mediated uptake or pinocytosis
has been reported (46). Further studies are in progress, focusing on the intracellular uptake of proanthocyanidin.
current therapies for hepatitis C patients are based on a combination
of pegylated recombinant interferons and ribavirin. However, viral
clearance is achieved by <60% of treated patients, and the therapies
are limited by significant side effects and high costs (47, 48).
Therefore, many novel anti-HCV drugs are currently under development,
most of which target viral enzymes. For example, BILN-2061, VX-950, and
SCH503034 are inhibitors of NS3/4A serine protease, and R1479 and
HCV-796 are inhibitors of NS5B RNA-dependent RNA polymerase (41, 48–53). NA255 is also an HCV replication inhibitor targeting the host sphingolipid biosynthesis (10).
These compounds are relatively low in molecular weight and can be
manufactured by organic synthesis. On the other hand, the anti-HCV
compound purified from blueberry leaves is a flavan-3-ol polymer with a
molecular mass of ~2 kDa. The highly polymerized structure that is
required for the efficient inhibition of HCV subgenome expression makes
synthesizing the anti-HCV proanthocyanidin difficult. However, because
proanthocyanidins are components of many plants and foods, daily intake
of proanthocyanidin is possible and may be beneficial against HCV
replication in hepatitis C patients. We estimate that fresh blueberry
leaf is rich in proanthocyanidin, which accounts for 3–4% of the weight.
Moreover, the polymerized status of blueberry leaf-derived
proanthocyanidin appears to be suitable for the inhibition of HCV
subgenome expression. Therefore, blueberry leaves might have potential
as a source of anti-HCV proanthocyanidin.
summary, we demonstrated that extracts of blueberry leaf possess strong
suppressive effects against HCV subgenome expression in a replicon cell
system. We identified the inhibitor as a proanthocyanidin oligomer with
an mDP value of ~8. Further studies of the mechanism underlying
proanthocyanidin-mediated HCV inhibition may open new ways to design
novel anti-HCV drugs.
thank Kazunori Nakata (Miyazaki Prefecture Industrial Technology
Research Center) for support in the EPMA analysis and Dr. Michinori
Kohara (The Tokyo Metropolitan Institute of Medical Science) for
providing HCV replicon cells.
1. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. (1989) Science 244, 359–362.
2. Seeff L. B. (1999) Am. J. Med. 107, 10S–15S.
Bisceglie A. M., Order S. E., Klein J. L., Waggoner J. G., Sjogren M.
H., Kuo G., Houghton M., Choo Q. L., Hoofnagle J. H. (1991) Am. J. Gastroenterol. 86, 335–338.
4. Myles D. C. (2001) Curr. Opin. Drug Discov. Devel. 4, 411–416.
5. Dillon J. F. (2004) J. Viral. Hepat. 11, Suppl. 1,
6. Ni Z. J., Wagman A. S. (2004) Curr. Opin. Drug Discov. Devel. 7, 446–459.
M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M.,
Reindollar R., Goodman Z. D., Koury K., Ling M., Albrecht J. K. (2001) Lancet 358, 958–965.
M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Gonçales F.
L., Jr., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin
A., Hoffman J., Yu J. (2002) N. Engl. J. Med. 347, 975–982.
Franceschi L., Fattovich G., Turrini F., Ayi K., Brugnara C., Manzato
F., Noventa F., Stanzial A. M., Solero P., Corrocher R. (2000) Hepatology 31, 997–1004.
H., Okamoto K., Aoki M., Kato H., Katsume A., Ohta A., Tsukuda T.,
Shimma N., Aoki Y., Arisawa M., Kohara M., Sudoh M. (2005) Nat. Chem. Biol. 1, 333–337.
11. Porter L. J., Hrstich L. N., Chan B. G. (1986) Phytochemistry 25, 223–230.
12. Shoji T., Masumoto S., Moriichi N., Akiyama H., Kanda T., Ohtake Y., Goda Y. (2006) J. Agric. Food Chem. 54, 884–892.
13. Guyot S., Marnet N., Drilleau J. F. (2001) J. Agric. Food Chem. 49, 14–20.
14. Gu L., Kelm M., Hammerstone J. F., Beecher G., Cunningham D., Vannozzi S., Prior R. L. (2002) J. Agric. Food Chem. 50, 4852–4860.
15. Tonge R., Shaw J., Middleton B., Rowlinson R., Rayner S., Young J., Pognan F., Hawkins E., Currie I., Davison M. (2001) Proteomics 1, 377–396.
16. Marouga R., David S., Hawkins E. (2005) Anal. Bioanal. Chem. 382, 669–678.
A., Jensen O. N., Podtelejnikov A. V., Sagliocco F., Wilm M., Vorm O.,
Mortensen P., Shevchenko A., Boucherie H., Mann M. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 14440–14445. [PMC free article]
18. Siridechadilok B., Fraser C. S., Hall R. J., Doudna J. A., Nogales E. (2005) Science 310, 1513–1515.
19. Hahm B., Kim Y. K., Kim J. H., Kim T. Y., Jang S. K. (1998) J. Virol. 72, 8782–8788. [PMC free article]
20. Lu H., Li W., Noble W. S., Payan D., Anderson D. C. (2004) J. Proteome Res. 3, 949–957.
21. Kim J. H., Paek K. Y., Ha S. H., Cho S., Choi K., Kim C. S., Ryu S. H., Jang S. K. (2004) Mol. Cell. Biol. 24, 7878–7890. [PMC free article]
22. Harris D., Zhang Z., Chaubey B., Pandey V. N. (2006) Mol. Cell. Proteomics 5, 1006–1018.
23. Kim C. S., Seol S. K., Song O. K., Park J. H., Jang S. K. (2007) J. Virol. 81, 3852–3865. [PMC free article]
24. Pacheco A., Reigadas S., Martínez-Salas E. (2008) Proteomics 8, 4782–4790.
25. Hwang B., Lim J. H., Hahm B., Jang S. K., Lee S. W. (2009) Biochem. Biophys. Res. Commun. 378, 584–588.
M., Sandercock A. M., Fraser C. S., Ridlova G., Stephens E., Schenauer
M. R., Yokoi-Fong T., Barsky D., Leary J. A., Hershey J. W., Doudna J.
A., Robinson C. V. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 18139–18144. [PMC free article]
27. Porter L. J. (1988) in The Flavonoids (Harbone J. B., editor. ed) pp. 21–63, Chapman and Hall Ltd., New York.
28. Arnold R. A., Noble A. C. (1978) Am. J. Enol. Vitic. 29, 150–152.
29. Brossaud F., Cheynier V., Noble A. C. (2001) Aust. J. Grape Wine Res. 7, 33–39.
30. Wilson M. A., Shukitt-Hale B., Kalt W., Ingram D. K., Joseph J. A., Wolkow C. A. (2006) Aging Cell 5, 59–68. [PMC free article]
31. Chen Z. P., Cai Y., Phillipson J. D. (1994) Planta Med. 60, 541–545.
32. Williams J. E. (2001) Altern. Med. Rev. 6, 567–579.
33. Sidwell R. W., Huffman J. H., Moscon B. J., Warren R. P. (1994) Chemotherapy 40, 42–50.
34. Gilbert B. E., Wyde P. R., Wilson S. Z., Meyerson L. R. (1993) Antiviral Res. 21, 37–45.
R., Sierra-Madero J., Cano-Dominguez C., Kershenovich J., Ortiz-Pedroza
G., Vazquez-Valls E., Garcia-Cosio C., Soria-Cordoba A., Armendariz A.
M., Teran-Toledo X., Romo-Garcia J., Fernandez H., Rozhon E. J. (1997) Antiviral Res. 35, 91–103.
36. Safrin S., McKinley G., McKeough M., Robinson D., Spruance S. L. (1994) Antiviral Res. 25, 185–192.
37. Barnard D. L., Smee D. F., Huffman J. H., Meyerson L. R., Sidwell R. W. (1993) Chemotherapy 39, 203–211.
38. Barnard D. L., Huffman J. H., Meyerson L. R., Sidwell R. W. (1993) Chemotherapy 39, 212–217.
39. Cheng H. Y., Lin C. C., Lin T. C. (2002) Antivir. Chem. Chemother. 13, 223–229.
40. Nahmias Y., Goldwasser J., Casali M., van Poll D., Wakita T., Chung R. T., Yarmush M. L. (2008) Hepatology 47, 1437–1445.
41. McCown M. F., Rajyaguru S., Le Pogam S., Ali S., Jiang W. R., Kang H., Symons J., Cammack N., Najera I. (2008) Antimicrob. Agents Chemother. 52, 1604–1612. [PMC free article]
42. Li D., Lott W. B., Martyn J., Haqshenas G., Gowans E. J. (2004) J. Virol. 78, 12075–12081. [PMC free article]
43. Pudi R., Ramamurthy S. S., Das S. (2005) J. Virol. 79, 9842–9853. [PMC free article]
44. Romero-López C., Díaz-González R., Berzal-Herranz A. (2007) Cell. Mol. Life Sci. 64, 2994–3006.
45. Xu L., Li B., Cheng M., Zhang W., Pan J., Zhang C., Gao H. (2008) Exp. Clin. Endocrinol. Diabetes 116, 215–224.
46. Kovtun Y. V., Goldmacher V. S. (2007) Cancer Lett. 255, 232–240.
47. Manns M. P., Wedemeyer H., Cornberg M. (2006) Gut 55, 1350–1359. [PMC free article]
48. Pawlotsky J. M., Gish R. G. (2006) Antivir. Ther. 11, 397–408.
49. Stauber R. E., Stadlbauer V. (2006) J. Clin. Virol. 36, 87–94.
D., Anderson P. C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bös
M., Cameron D. R., Cartier M., Cordingley M. G., Faucher A. M., Goudreau
N., Kawai S. H., Kukolj G., Lagacé L., LaPlante S. R., Narjes H.,
Poupart M. A., Rancourt J., Sentjens R. E., St George R., Simoneau B.,
Steinmann G., Thibeault D., Tsantrizos Y. S., Weldon S. M., Yong C. L.,
Llinàs-Brunet M. (2003) Nature 426, 186–189.
H. W., Zeuzem S., Weegink C. J., Forestier N., van Vliet A., van de
Wetering de Rooij J., McNair L., Purdy S., Kauffman R., Alam J., Jansen
P. L. (2006) Gastroenterology 131, 997–1002.
C., Kieffer T. L., Bartels D., Hanzelka B., Müh U., Welker M.,
Wincheringer D., Zhou Y., Chu H. M., Lin C., Weegink C., Reesink H.,
Zeuzem S., Kwong A. D. (2007) Gastroenterology 132, 1767–1777.
C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S. K.,
Hussain M., Shah A., Cutler D., Zhang J., Zeuzem S. (2007) Gastroenterology 132, 1270–1278.
back to top | HOME | Where to Get Blueberry Leaf Extract w/